Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep

Oliviero Bruni 1,*, Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4

1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy
2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; ferinistrambi.luigi@hsr.it
3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy
4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.)

* Correspondence: oliviero.bruni@uniroma1.it; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941

Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or disruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control. Currently available evidence suggests that herbal extracts may exert some of their hypnotic and anxiolytic activity through interacting with GABA receptors and modulating GABAergic signaling in the brain, but their mechanism of action in the treatment of insomnia is not completely understood.

Keywords: gamma-aminobutyric acid; GABA receptors; sleep; insomnia; herbal medicine

1. Introduction

Sleep is a fundamental physiological process required to maintain physical and emotional well-being. Healthy sleep is a crucial process for optimal cognitive performance, including attention, emotional reactivity, and learning and memory [1]. Sleep also contributes to a wide range of other physiological processes, e.g., metabolic and endocrine health and the strengthening of the immune system [2,3]. Chronic insomnia affects people across all geographies, socioeconomic levels, and cultures; because of this, sleeping pills are among the most frequently prescribed medicines worldwide [1,2].

It should be noted that multiple approved therapies for insomnia come with a safety warning, and some hypnotics (including, for example, barbiturates) have been abandoned because of unfavorable adverse event profiles or substance abuse [4]. In contrast, most herbal medicines for insomnia and anxiety offer an exceptional safety profile, sometimes with tenfold fewer adverse events than with pharmacotherapy [5–7]. Recent surveys suggest that almost two-thirds of individuals with sleep problems do not consult their doctor but search for treatment advice online, and herbal medicine remains a popular choice [8–11]. A number of recent studies demonstrate a steady increase in the uptake of complementary and alternative medicines for insomnia; the reasons for this increase may include dissatisfaction or concern for side effects with pharmacological treatment, previous positive experiences, and self-perceived effectiveness of alternative medicine [9,11,12].

Citation: Bruni, O.; Ferini-Strambi, L.; Giacomoni, E.; Pellegrino, P. Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep. Nutrients 2021, 13, 530. https://doi.org/10.3390/nu13020530

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Although their effectiveness is heavily debated, several herbal therapies for insomnia have been used for centuries, and many products, including valerian (Valeriana officinalis L.) and chamomile (Matricaria sp.), are still widely used today because of their good safety profile and their proposed anxiolytic and sedative properties [10,13–17].

Pharmacologically, herbal and traditional medicines represent complex mixtures of hundreds of constituents, making it difficult to isolate the active components and determine their exact mechanism of action [18]. Studies of several herbal remedies used for insomnia highlighted that changes in the central GABAergic neurotransmission could be responsible for the anxiolytic and the sedative properties of these remedies [13]. This is not surprising, as gamma-aminobutyric acid (GABA) is recognized as one of the main neurotransmitters responsible for sleep regulation. GABA_A receptor modulation is one of the four key mechanisms of action of the approved pharmacological therapies for insomnia (the other three mechanisms are melatonin receptor agonism, histamine 1 receptor antagonism, and hypocretin/orexin antagonism) [1].

The aim of this review is to summarize the current knowledge of the GABA receptors in sleep regulation and to perform a systematic analysis of literature addressing the GABAergic mechanisms of action of herbal remedies for insomnia.

2. Stages of Sleep

Three distinct vigilance states can be identified on the basis of the level of arousal and electroencephalogram (EEG) activity: wakefulness, non-rapid eye movement (NREM), and rapid eye movement (REM) [2]. Healthy, young individuals usually experience several NREM and REM cycles during the night; the typical length of one NREM–REM cycle in humans is approximately 90 min [2,19].

The three vigilance states are regulated by wakefulness-promoting, NREM-promoting, and REM-promoting distinct neuronal groups (nuclei) located in the basal forebrain, thalamus, and brainstem [2,20]. Brain nuclei promoting different vigilance states exert reciprocally inhibitory activity and are involved in modulating the activity of numerous other structures of the central nervous system [2,20,21].

Wakefulness is regulated by a number of different neurotransmitter systems, including acetylcholine, serotonin, norepinephrine, histamine, orexins, neuropeptide S, dopamine, glutamate, and even GABA [2]. In the brainstem, the pontine locus coeruleus promotes wakefulness via excitatory connections to the cerebral cortex and inhibitory connections to sleep-promoting nuclei [22]. The alternation of NREM and REM sleep phases during the night is likely controlled by several mechanisms, including a reciprocal interaction of “REM-on” glutamatergic neurons in the pontine/mesencephalic reticular formation and “REM-off” norepinephrine-serotonin neurons in the dorsal raphe and the locus coeruleus [2,20]. Transition between vigilance states is orchestrated by the central pacemaker: the suprachiasmatic nucleus [20,23]. As the most widespread inhibitory neurotransmitter in the brain, GABA plays a role in inhibiting both “REM-on” and “REM-off” neurons in the brainstem and in regulating transitions between REM sleep and wakefulness or NREM sleep [2,23]. In addition, various groups of GABA neurons outside the brainstem are involved in the control of circadian timing and homeostatic regulation of sleep [2].

3. The Role of GABAergic Signaling in Sleep Physiology

As a major inhibitory neurotransmitter, GABA helps maintain the overall balance of neuronal excitation and inhibition in the central nervous system and plays one of the central roles in brain development and function [24]. Over 20% of all neurons in the brain are estimated to be GABAergic [25]. Three different GABA receptors, GABA_A, GABA_B, and GABA_C, are involved in the regulation of sleep and arousal (albeit to different extents) [2,25]. The most commonly used hypnotics exert their effect on GABA systems, most notably through allosteric modulation of the benzodiazepine site [26–28]. Similarly, many herbal medicines have been proposed to enhance GABAergic signaling, many through interactions with the GABA_A receptor [13].
3.1. GABA\textsubscript{A} Receptor

The fast-acting ionotropic GABA\textsubscript{A} receptors were the first to be discovered and have been the target of three generations of anxiolytics and hypnotics [1,2,29]. GABA\textsubscript{A} receptors are pentameric, ligand-gated Cl\textsuperscript{−} ion channels; the classical synaptic subtypes are formed of two \( \alpha \), two \( \beta \), and one \( \gamma \) or \( \delta \) subunit, the \( \alpha 1 \beta 2 \gamma 2 \) receptor being the most abundant [29,30] (Figure 1).

![Figure 1. The structure of the GABA\textsubscript{A} receptor and the location of common agonist and antagonist binding sites [26,29–31]. Cl\textsuperscript{−}, chlorine ions; GABA, gamma-aminobutyric acid; EtOH, ethanol.](image)

Barbiturates were the first generation of sedative/hypnotic drugs introduced in the early 20th century. Their binding site on the GABA\textsubscript{A} receptor is different from that of GABA, and they act via direct activation of the receptor. Barbiturates do not show selective affinity to different receptor compositions of GABA\textsubscript{A}. Second-generation sleep aids (benzodiazepines) are GABA\textsubscript{A} allosteric modulators that bind to the interface between the \( \alpha \) and the \( \gamma \) subunits across a range of receptor compositions [27,29,31]. Recently developed third-generation non-benzodiazepine hypnotics include, among others, zopiclone (a cyclopyrrolone), zolpidem (an imidazopyridine), and zaleplon (a pyrazolopyrimidine), which are sometimes collectively called the “Z drugs” [32]. All GABA\textsubscript{A} agonists help with entering and maintaining sleep by suppressing REM sleep and lower frequency waves while promoting high frequency waves [19]. The effects of GABA\textsubscript{A} agonists on sleep stages may vary; for example, eszopiclone does not have any effect on the length of NREM or REM sleep [33]. Reductions in theta and alpha frequencies have been observed in older, but not in young, adults with zolpidem; moreover, zolpidem decreased Stage 1 NREM in older adults, with no other age-related changes in sleep parameters [34].

3.2. GABA\textsubscript{B} Receptor

GABA\textsubscript{B} receptors are slow-acting metabotropic G-protein-linked dimers containing one GABA\textsubscript{B1} (GABA\textsubscript{B1a} or GABA\textsubscript{B1b}) and one GABA\textsubscript{B2} subunit [25,28,29] (Figure 2). Fewer drugs have been developed to target the GABA\textsubscript{B} receptor, baclofen being the most popular agonist, and there are less clinical data available than for the GABA\textsubscript{A} receptor [27,35]. Although GABA\textsubscript{B} agonists may promote sleep by increasing the duration of NREM and REM sleep, the effect is believed to be largely off-target [28,36]. Binding to the GABA\textsubscript{B}
receptor may be responsible for the sleep-promoting effects of the drug gamma hydroxybutyrate. Activation of GABA\textsubscript{B} receptors on hypocretin/orexin neurons increases the power and duration of slow wave sleep and decreases the frequency of transitions between wakefulness and REM sleep [37,38].

![Figure 2](image-url)  
*Figure 2.* The structure of the GABA\textsubscript{B} receptor, its ligand binding site, and the downstream signaling elements [39,40]. GABA, gamma-aminobutyric acid; LB, ligand binding.

### 3.3. GABA\textsubscript{C} Receptor

The subclass of GABA\textsubscript{A} receptors containing ρ subunits is often called GABA\textsubscript{C} or GABA-ρ; they belong to the same family of fast-acting pentameric, ligand-gated Cl\textsuperscript{−} ion channels as GABA\textsubscript{A} [25,27,41] (Figure 3). Although both GABA\textsubscript{A} and GABA\textsubscript{C} receptors bind GABA, they have separate sets of agonists and antagonists. GABA\textsubscript{C} receptors are more sensitive to GABA than the other two receptor subclasses [25].

![Figure 3](image-url)  
*Figure 3.* The structure and the ligand-binding site of the GABA\textsubscript{C} receptor [41]. CACA, cis-4-aminocrotonic acid; GABA, gamma-aminobutyric acid; p1–5, GABA\textsubscript{C} ρ subunits 1–5; TPMPA, (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid.

A selective GABA\textsubscript{C} antagonist (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) has been shown to decrease the relative duration of NREM and REM sleep in rats [42]. In contrast, the selective partial GABA\textsubscript{C} agonist cis-4-aminocrotonic acid (CACA) does not have any effect on the relative duration of REM sleep [43].
A number of studies suggest that different classes of GABA receptors may play varying roles in sleep control, e.g., promoting different phases of sleep [25]. The expression pattern of each class and the cellular localization (synaptic or extrasynaptic) may play a role in the extent of the receptor involvement in sleep control [19]. This involvement may be influenced by other physiological and pathological conditions; for example, sleep deficits in slow wave sleep recorded in patients with schizophrenia may be specifically linked to the GABA_B receptor [44]. Although most of the currently available hypnotics target GABA_A, ongoing research on the physiology and pharmacology of the other two types of GABA receptors may lead to development of therapies for insomnia targeting GABA_B or GABA_C.

4. Herbal Remedies Acting on GABA Metabolism and Function

Herbal medicine, i.e., applications of plants or plant-derived materials for therapeutic purposes, has been used for centuries to treat a range of sleep disorders; notable examples include valerian (Valeriana officinalis L.), passionflower (Passiflora incarnata L.), lemon balm (Melissa officinalis L.), and Californian poppy (Eschscholzia californica Cham.) [13,16]. More recently, therapies being tested for efficacy in insomnia have included combinations of herbal extracts with melatonin and vitamin B6 [45]. A growing body of recent research has been dedicated to dissecting the content of naturally derived sleep aids and to determining the specific compounds responsible for their sedative properties. Multiple mechanisms of actions have been proposed, including those that promote GABAergic signaling, most commonly through an interaction of the active component with the GABA_A receptor [6,13,46].

4.1. Systematic Literature Review

We have searched PubMed and Google Scholar for publications describing GABAergic effects of herbal medicines and their active components that could explain their mechanism of action in sleep regulation. The search terms included (“herbal medicine” OR “herb”) AND (“GABA” OR “gammaaminobutyric acid” OR “gamma aminobutyric acid”) AND (“sleep” OR “hypnotic” OR “sedative”).

The PubMed search returned 63 results; after removing reviews, articles not in English, and studies that did not assess GABAergic effects or sleep, 31 results were included. A number of additional publications were identified through Google Scholar searches; after removing duplicates, 11 additional articles were added to the reference library (Figure 4).

Figure 4. PRISMA flow diagram. GABA, gamma-aminobutyric acid; PRISMA, preferred reporting items for systematic reviews and meta-analyses.
4.2. Natural Compounds Acting on GABA<sub>A</sub>, GABA<sub>B</sub>, and GABA<sub>C</sub>

We analyzed the articles identified in the literature search for the description of specific mechanisms of action targeting GABAergic signaling in sleep. The results of the literature analysis are shown in Table 1.

**Table 1.** Common medicinal plants with known sleep-inducing properties that target GABAergic signaling.

| Latin and Common Name | Known Chemical Components | Known Effect on Sleep | Target | Model | References |
|-----------------------|---------------------------|-----------------------|--------|-------|------------|
| **Individual Plants**  |                           |                       |        |       |            |
| Valeriana officinalis L. (Valerian) | Alkaloids, terpenes, organic acids and their derivatives, valepotriates, and flavones | Reduces sleep latency, improves subjective measures | GABA<sub>A</sub> receptor | In vitro studies; clinical studies | [47–51] |
| Magnolia sp. | Magnolol and honokiol | Promotes REM sleep | GABA<sub>A</sub> receptor | In vitro studies; i.p. administration in mice | [52–54] |
| Schisandra chinensis (Turcz.) Baill. (Chinese magnolia-vine, Magnolia berry) | Schizandrin B | Promotes sleep | GABA<sub>A</sub> receptor | i.p. administration in mice and male rats | [55–57] |
| Artemisia sp. | Benzodiazepines | Reduces sleep latency | GABA<sub>A</sub> receptor | | |
| Nelumbo nucifera Gaertn. (Lotus) | Nuciferine, alkaloids | Promotes sleep | GABA<sub>A</sub> receptor | In vitro studies | [60] |
| Moringa oleifera Lam. (Drumstick tree) | Oleic acid, β-Sitosterol, and Stigmasterol | Increases sleep quality | GABA<sub>A</sub> receptor | p.o. administration in male mice | [61] |
| Piper methysticum L. (Kava-kava) | Kavapyrones | Decreases sleep latency; no effect on NREM sleep | GABA<sub>A</sub> receptor (not benzodiazepine site) | p.o. administration in mice | [62] |
| Zizyphus jujube (Jujube, or red date) | Sanjoinine A, suanzaorentang | Improves sleep quality, prolonging sleep time and increasing NREM sleep | GABA<sub>A</sub> receptor; activation of GABA synthesis through enhanced expression of GAD; serotonin receptors | i.p. and p.o. administration in male rats | [63,64] |
| Passiflora incarnata (Passionflower) | Apigenin, alkaloids, flavones | Reduces sleep latency, increases sleep duration | GABA<sub>A</sub> and GABA<sub>B</sub> receptors, (and possibly GABA<sub>C</sub> receptor) | In vitro studies; p.o. administration in mice | [65,66] |
| Withania somnifera L. (Indian ginseng) | Withanolide A, withaferin A | Reduces sleep latency, improves sleep quality | GABA<sub>A</sub> and GABA<sub>C</sub> receptors | In vitro studies; clinical studies | [67,68] |
| Eschscholzia californica Cham. (California poppy) | Alkaloids | Improves sleep latency and duration | GABA<sub>A</sub> receptor; serotonin receptor | In vitro studies | [69] |
| Polygonum tenuifolium Willd. (Yuan Zhu) | Tenufolin | Increases sleep duration | Increases the levels of GABA and GABA transporter 1 | Zebrafish and rats | [70,71] |
| Melissa officinalis L. (Lemon balm) | Rosmarinic acid | Improves sleep quality | Decreases the level of GABA transaminase | In vitro studies; i.p. administration in mice | [72] |
| Ginkgo biloba L. (Ginkgo) | Ginkgotoxin, flavonoids, terpenoids | Improves subjective sleep quality measures | Inhibition of GAD activity | Clinical studies | [73] |
| Hypericum perforatum L. (St John’s Wort) | Hypericin, pseudohypericin, hyperoside, among others | Increases REM latency and deep sleep | Inhibition of GAD and GABA transporter activity | Clinical studies | [74] |
The vast majority of herbal medicines acted through the GABA<sub>A</sub> receptor (mostly via binding to the GABA or benzodiazepine sites) (Figure 1). The specific chemicals that serve as natural modulators of the GABA<sub>A</sub> receptor (alkanes and alkaloids, flavones, flavonoids and isoflavonoids, phenols, terpenes, coumarins, etc.) have been described in detail in a recent review that addressed the specific pharmacological features of their interactions with the receptor [46]. Here, we present a broader summary of herbal extracts that may be used to regulate sleep, possibly acting via GABAergic signaling.

The largest body of evidence for GABA<sub>A</sub> modulation is associated with valerian root (Valeriana officinalis L.), which is widely used to reduce the latency of sleep onset and increase sleep quality [13,79]. Valerian root extract contains over 150 chemical constituents including alkaloids, terpenes, organic acids and their derivatives, valepotriates and flavones [13,48]. GABA itself may be present in the valerian extracts, although its bioavailability is questionable [5]. Notably, small differences have been reported between extracts from plants grown in different conditions or processed in a different manner, and large-scale producers have standardized protocols of plant growth and extract preparation aimed at reducing variability [48]. Studies in tissue culture and animal models suggest that components of valerian extract (Valeriana officinalis L.) possess prominent dose-dependent GABA<sub>A</sub> agonistic activity [49,51]. 6-methylapigenin is a potent positive modulator of GABA<sub>A</sub>, possibly binding to the benzodiazepine site at the interface of α and γ subunits, whereas valerenic acid and valerenol have been shown to interact with the β subunit of the receptor [47,48].

Magnolia sp., Artemisia sp., Chinese magnolia vine (Schisandra chinensis), lotus (Nelumbo nucifera), and drumstick tree (Moringa oleifera) have all been shown to contain GABA<sub>A</sub> agonists that promote sleep in various animal models. A potent GABAergic effect via the GABA<sub>A</sub> receptor (benzodiazepine site) has been demonstrated for herbal mixes used in traditional medicine in Japan (yokukansan) and China (suanzaorentang); however, the specific herbs and compounds responsible for the effect remain to be identified [76,78]. A number of different approaches can be used to identify these compounds; for example, in one study, an in silico screen of a traditional Chinese medicine library was performed and found that 2-O-cafeoyl tartaric acid, 2-O-feruloyl tartaric acid, and mumefural are potent GABA<sub>A</sub> receptor agonists at both GABA and benzodiazepine binding sites [80]. Tartaric acid derivatives are present in various fruit syrups and juices, and mumefural is derived...
from the processed fruit of Japanese apricot (Prunus mume Sieb. et Zucc.) (a traditional health food) [81].

Extract of dried flowers of chamomile (Matricaria sp.) has been used as a mild tranquilizer and sleep inducer for thousands of years and contains 28 terpenoids and 36 flavonoids [82,83]. Among them, apigenin has been shown to exhibit a hypnotic activity by activating the GABA<sub>A</sub> receptor at the benzodiazepine binding site [26,46,82]. Apigenin is an active component of several herbal sleep remedies such as passionflower (Passiflora incarnata L.), which is used to reduce sleep latency and increase sleep duration [13,46]. Other GABA<sub>A</sub> allosteric modulators acting at the benzodiazepine site include alkaloids isolated from the California poppy (Eschscholzia californica Cham.), which is used to induce relaxation and sleep [69].

There is much less evidence of herbal medicines interacting with the GABA<sub>B</sub> or the GABA<sub>C</sub> receptors. The extract of Passiflora incarnata has been shown to inhibit the binding of ligands to both GABA<sub>A</sub> and GABA<sub>B</sub> receptors in a concentration-dependent manner, suggesting that it contains antagonists of both receptor subtypes [65]. Notably, Passiflora incarnata L. extract contains a high amount of GABA and therefore has a potential to exert its hypnotic activity through all three types of GABA receptors, although its exact mechanism of action remains to be demonstrated [66]. The aqueous root extract of Indian ginseng (Withania somnifera L.) has been shown to act as a potent agonist of the GABA<sub>C</sub> receptor in addition to weakly activating GABA<sub>A</sub> [67]. Various natural compounds have been implicated in the plant’s mechanism of action, including withanone, withaferin A, and triethylene glycol [67,84].

4.3. Other Mechanisms of Action Related to GABA Signaling

Several indirect effects on GABA signaling have been reported for various medicinal plant extracts. Valerian root extract (Valeriana officinalis L.) may mediate inhibition of enzymatic destruction of GABA, increasing GABA availability [5]. Extract of Melissa officinalis L. decreases the level of GABA transaminase in hippocampal neurons [72]. Unidentified components of a Mexican tree Ternstroemia lineata DC. have been shown to promote GABA release in mouse brain slices [85]. Tenufolin, the active component of Polygala tenuifolia, increases the expression of GABA transporter 1 and GABA availability in animal models [70,71]. Activation of GABA synthesis through enhanced expression of glutamic acid decarboxylase (GAD) has been demonstrated for sanjoinine A, an alkaloid isolated from jujube (Zizyphus jujuba) [63]. Finally, although the Citrus aurantium essential oil exerts its anxiolytic effect via the serotonin receptor, an indirect effect on GABAergic system has been described as well [75,86]. These results suggest that herbal sleep medicines may have a plethora of direct and indirect effects on GABAergic signaling beyond direct interaction with GABA receptors.

5. Discussion and Conclusions

Insomnia is a widespread, often chronic, disorder that affects 5–15% of the general population and is associated with a great reduction in quality of life [1,2,87]. Among prescription medicines for insomnia, many therapies act via modulation of GABAergic signaling, including potent hypnotics such as benzodiazepines and “Z drugs” that bind to various sites on the GABA<sub>A</sub> receptor [1,27,30]. Although GABA<sub>B</sub> and GABA<sub>C</sub> receptors have distinct roles in controlling various stages of sleep, none of the currently approved prescription medicines target these receptor subtypes; however, ongoing research may lead to the development of such medicines in the future.

The ability of herbal extracts to reduce sleep latency, increase sleep duration, and improve sleep quality has been explored in numerous studies; however, robust clinical evidence supporting their use for the treatment of insomnia is currently lacking, emphasizing the need for research in this area [87,88]. Mechanistic studies have shown that herbal medicines used for the treatment of insomnia may exert their effect through various mechanisms of action. Components of ginseng (Withania
somnifera L.), Ginkgo biloba L., and St John’s Wort (Hypericum perforatum L.) have been shown to influence the reuptake of neurotransmitters, such as norepinephrine, dopamine, and serotonin [70,89,90]. Extracts of jujube seeds and valerian (Valeriana officinalis L.) directly interact with serotonin receptors [64,89], and Griffonia simplicifolia Baill. contains 5-hydroxytryptophan, a natural precursor of serotonin [91]. L-theanine, which is found in green tea, has been discovered to potentiate GABA, dopamine, and serotonin receptors and to inhibit glutamate reuptake [92]. Active components of lavender (Lavandula angustifolia Miller) can bind the glutamate N-methyl-D-aspartate receptors and serotonin transporters [93]. Finally, several herbal substances may interact with glutamic acid decarboxylase or modulate GABA and serotonin receptors [6,88,94]. Sleep-promoting GABAergic neurons represent the main cellular target of pharmacological therapies for insomnia, and GABA signaling appears to be the target of a large number of over-the-counter herbal sleep aids [1,2,13]. The exceptional safety profile of herbal medicines, especially when compared with pharmacotherapy for insomnia, and their wide acceptance by patients, serve as a strong argument in favor of further investigations that aim to define their mechanism of action more precisely and that aim to confirm their clinical efficacy in terms of specific sleep parameters.

In conclusion, despite the availability of multiple hypnotic drugs, side effects remain an issue, and there is ongoing demand for safer treatment options for insomnia. The evidence reviewed here suggests that multiple plant-derived substances may serve as sleep aids by modulating GABAergic signaling in the brain. The exceptional safety profile of herbal medicines and their wide acceptance by patients serve as a strong argument in favor of further investigations of their mechanism of action and identification of specific compounds that exert the hypnotic effect.

Author Contributions: All authors discussed and agreed on the concept of the review. PP and EG drafted the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: Editorial support was provided by Olga Ucar and Ella Palmer of inScience Communications, Springer Healthcare Ltd., UK and was funded by Sanofi.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The study did not report any data; all references used in the review are included in the reference list.

Acknowledgments: The authors thank Claire Bertin and Lamia Achour of Sanofi Consumer Health-Care for providing helpful scientific insight throughout manuscript development.

Conflicts of Interest: O.B. and L.F.-S. declare no conflicts of interest. EG and PP are employees of Sanofi.

References
1. Avidan, A.Y.; Neubauer, D.N. Chronic Insomnia Disorder. Continuum (Minneap Minn) 2017, 23, 1064–1092. [CrossRef]
2. Brown, R.E.; Basheer, R.; McKenna, J.T.; Strecker, R.E.; McCarley, R.W. Control of Sleep and Wakefulness. Physiol. Rev. 2012, 92, 1087–1187. [CrossRef] [PubMed]
3. Leproult, R.; Van Cauter, E. Role of sleep and sleep loss in hormonal release and metabolism. Endocr. Dev. 2010, 17, 11–21. [CrossRef] [PubMed]
4. Kripke, D.F. Hypnotic drug risks of mortality, infection, depression, and cancer: But lack of benefit. F1000Research 2016, 5, 918. [CrossRef] [PubMed]
5. Monograph. Valeriana officinalis. Altern. Med. Rev. 2004, 9, 438–441.
6. Awad, R.; Levac, D.; Cybulska, P.; Merali, Z.; Trueau, V.L.; Arnason, J.T. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can. J. Physiol. Pharmacol. 2007, 85, 933–942. [CrossRef] [PubMed]
7. Schulz, V. Safety of St. John’s Wort extract compared to synthetic antidepressants. Phytomedicine 2006, 13, 199–204. [CrossRef] [PubMed]
8. Philips. The global pursuit of better sleep health. In Global Sleep Survey; Philips: Amsterdam, The Netherlands, 2019.
9. Welz, A.N.; Emberger-Klein, A.; Menrad, K. Why people use herbal medicine: Insights from a focus-group study in Germany. BMC Complementary Altern. Med. 2018, 18. [CrossRef] [PubMed]
10. Zhang, H.; Liu, P.; Wu, X.; Zhang, Y.; Cong, D. Effectiveness of Chinese herbal medicine for patients with primary insomnia: A PRISMA-compliant meta-analysis. *Medicine (Baltimore)* 2019, 98, e15967. [CrossRef]

11. Frass, M.; Strassl, R.P.; Friehs, H.; Mullner, M.; Kundi, M.; Kaye, A.D. Use and acceptance of complementary and alternative medicine among the general population and medical personnel: A systematic review. *Ochsner J.* 2012, 12, 45–56.

12. Ashraf, M.; Saeed, H.; Saleem, Z.; Rathore, H.A.; Rasool, F.; Tahir, E.; Bhatti, T.; Khalid, J.; Bhatti, T.; Tariq, A. A cross-sectional assessment of knowledge, attitudes and self-perceived effectiveness of complementary and alternative medicine among pharmacy and non-pharmacy university students. *BMC Complementary Altern. Med.* 2019, 19, 95. [CrossRef] [PubMed]

13. Shi, Y.; Dong, J.W.; Zhao, J.H.; Tang, L.N.; Zhang, J.J. Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence. *Curr. Neuropsychopharmacol.* 2014, 12, 289–302. [CrossRef] [PubMed]

14. Yeung, W.F.; Chung, K.F.; Poon, M.M.; Ho, F.Y.; Zhang, S.P.; Zhang, Z.J.; Ziea, E.T.; Wong, V.T. Chinese herbal medicine for insomnia: A systematic review of randomized controlled trials. *Sleep Med. Rev.* 2012, 16, 497–507. [CrossRef] [PubMed]

15. Xie, C.L.; Gu, Y.; Wang, W.W.; Lu, L.; Fu, D.L.; Liu, A.J.; Li, H.Q.; Li, J.H.; Lin, Y.; Tang, W.J.; et al. Efficacy and safety of Suanzaoren decoction for primary insomnia: A systematic review of randomized controlled trials. *BMC Complementary Altern. Med.* 2013, 13, 18. [CrossRef] [PubMed]

16. Spiegelhalter, K.; Nissen, C.; Riemann, D. Clinical Sleep—Wake Disorders II: Focus on Insomnia and Circadian Rhythm Sleep Disorders. In *Sleep-Wake Neurobiology and Pharmacology*; Landolt, H.-P., Dijk, D.-J., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 261–276. [CrossRef]

17. Meolie, A.L.; Rosen, C.; Kristo, D.; Kohrman, M.; Gooneratne, N.; Aguillard, R.N.; Fayle, R.; Troell, R.; Townsend, D.; Claman, D.; et al. Oral nonprescription treatment for insomnia: An evaluation of products with limited evidence. *J. Clin. Sleep Med.* 2005, 1, 173–187. [CrossRef]

18. World Health Organization. *National Policy on Traditional Medicine and Regulation of Herbal Medicines*; World Health Organization: Geneva, Switzerland, 2005.

19. Steiger, A. Sleep and Its Modulation by Substances That Affect GABAA Receptor Function. In *GABA and Sleep: Molecular, Functional and Clinical Aspects*; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 121–146. [CrossRef]

20. Pal, D.; Mallick, B.N. GABAergic Modulation of Pontine Cholinergic and Noradrenergic Neurons for REM Sleep Generation. In *GABA and Sleep: Molecular, Functional and Clinical Aspects*; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 199–212. [CrossRef]

21. Szabadi, E. Selective targets for arousal-modifying drugs: Implications for the treatment of sleep disorders. *Drug Discov. Today* 2014, 19, 701–708. [CrossRef] [PubMed]

22. Szabadi, E. Functional neuroanatomy of the central noradrenergic system. *J. Psychopharmacol.* 2013, 27, 659–693. [CrossRef] [PubMed]

23. Reinoso-Suárez, F.; de la Roza, C.; Rodrigo-Angulo, M.L.; de Andrés, I.; Nuñez, Á.; Garzón, M. GABAergic Mechanisms in the Ventral Oral Pontine Tegmentum: The REM Sleep—Induction Site—In the Modulation of Sleep—Wake States. In *GABA and Sleep: Molecular, Functional and Clinical Aspects*; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 233–252. [CrossRef]

24. Möhler, H. Physiology and Pharmacology of the GABA System: Focus on GABA Receptors. In *GABA and Sleep: Molecular, Functional and Clinical Aspects*; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 3–23. [CrossRef]

25. Gottesmann, C. Function of GABAB and ρ-Containing GABAA Receptors (GABAC Receptors) in the Regulation of Basic and Higher Integrated Sleep-Waking Processes. In *GABA and Sleep: Molecular, Functional and Clinical Aspects*; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 169–188. [CrossRef]

26. Chebib, M.; Hanrahan, J.R.; Mewett, K.N.; Duke, R.K.; Johnston, G.A.R. Ionotropic GABA Receptors as Therapeutic Targets for Memory and Sleep Disorders. In *Annual Reports in Medicinal Chemistry*; Elsevier: Amsterdam, The Netherlands, 2004; pp. 13–23. [CrossRef]

27. Vargas, R. The GABAergic System: An Overview of Physiology, Physiopathology and Therapeutics. *Int. J. Clin. Pharmacol. Pharmacother.* 2018, 3. [CrossRef]

28. Wisden, W.; Yu, X.; Franks, N.P. GABA Receptors and the Pharmacology of Sleep. In *Sleep-Wake Neurobiology and Pharmacology*; Landolt, H.-P., Dijk, D.-J., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 279–304. [CrossRef]

29. Natt, D. GABA Receptors: Subtypes, regional distribution, and function. *J. Clin. Sleep Med.* 2006, 2, S7–S11. [CrossRef] [PubMed]

30. Bhattacharjee, A.; Wallner, M.; Lindemeyer, A.K.; Olsen, R.W. GABA Receptor Physiology and Pharmacology. In *The Oxford Handbook of Neuronal Ion Channels*; Oxford University Press: Oxford, UK, 2018. [CrossRef]

31. Uusi-Oukari, M.; Korpi, E.R. Regulation of GABAA Receptor Subunit Expression by Pharmacological Agents. *Pharmacol. Rev.* 2010, 62, 97–135. [CrossRef]

32. Staner, L.; Cornette, F.; Otman, S.; Nedelec, J.-F.; Danjou, P. Zolpidem in the Treatment of Adult and Elderly Primary Insomnia Patients. In *GABA and Sleep: Molecular, Functional and Clinical Aspects*; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 383–411. [CrossRef]

33. Monti, J.M.; Pandi-Perumal, S.R. Eszopiclone: Its use in the treatment of insomnia. *Neuropsychiatr. Dis. Treat.* 2007, 3, 441–453. [PubMed]
34. Chinoy, E.D.; Grey, D.J.; Kaslovsky, D.N.; Meyer, F.G.; Wright, K.P., Jr. Age-related changes in slow wave activity rise time and NREM sleep EEG with and without zolpidem in healthy young and older adults. Sleep Med. 2014, 15, 1037–1045. [CrossRef] [PubMed]

35. Enna, S.J. GABAB receptor agonists and antagonists: Pharmacological properties and therapeutic possibilities. Expert Opin. Investig. Drugs 2005, 6, 1319–1325. [CrossRef] [PubMed]

36. Vienne, J.; Bettler, B.; Franken, P.; Tafti, M. Differential effects of GABAB receptor subtypes, γ-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation. J. Neurosci. 2010, 30, 14194–14204. [CrossRef] [PubMed]

37. Wetter, T.C.; Beitinger, P.A.; Beiting, M.E.; Wollweber, B. Pathophysiology of Sleep Disorders. In GABA and Sleep: Molecular, Functional and Clinical Aspects; Monti, J.M., Pandi-Perumal, S.R., Möhler, H., Eds.; Springer: Basel, Switzerland, 2010; pp. 325–361. [CrossRef]

38. Landolt, H.-P.; Holst, S.C.; Valomon, A. Clinical and Experimental Human Sleep-Wake Pharmacogenetics. In Sleep-Wake Neurobiology and Pharmacology; Landolt, H.-P., Dijk, D.-J., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 207–241. [CrossRef]

39. Benarroch, E.E. GABAB receptors: Structure, functions, and clinical implications. Neurology 2012, 78, 578–584. [CrossRef]

40. Geng, Y.; Bush, M.; Mosyak, L.; Wang, F.; Fan, Q.R. Structural mechanism of ligand activation in human GABA(B) receptor. Nature 2013, 504, 254–259. [CrossRef] [PubMed]

41. Naffaa, M.M.; Hung, S.; Chebib, M.; Johnston, G.A.R.; Hanrahan, J.R. GABA-ρ receptors: Distinctive functions and molecular pharmacology. Br. J. Pharmacol. 2017, 174, 1881–1894. [CrossRef]

42. Arnaud, C.; Gauthier, P.; Gottesmann, C. Study of a GABAC receptor antagonist on sleep-waking behavior in rats. Psychopharmacology (Berlin) 2001, 154, 415–419. [CrossRef] [PubMed]

43. Ulloor, J.; Mavani, V.; Saha, S.; Siwek, D.F.; Datta, S. Spontaneous REM sleep is modulated by the activation of the pedunculopontine tegmental GABAB receptors in the freely moving rat. J. Neurophysiol. 2004, 91, 1822–1831. [CrossRef] [PubMed]

44. Kantrowitz, J.; Citrome, L.; Javitt, D. GABA(B) receptors, schizophrenia and sleep dysfunction: A review of the relationship and its potential clinical and therapeutic implications. CNS Drugs 2009, 23, 681–691. [CrossRef] [PubMed]

45. Lemoine, P.; Bablon, J.-C.; Da Silva, C. A combination of melatonin, vitamin B6 and medicinal plants in the treatment of mild-to-moderate insomnia: A prospective pilot study. Complementary Ther. Med. 2019, 45, 104–108. [CrossRef] [PubMed]

46. Cieck, S.S. Structure-Dependent Activity of Natural GABA(A) Receptor Modulators. Molecules 2018, 23, 1512. [CrossRef] [PubMed]

47. Benke, D.; Barberis, A.; Kopp, S.; Altmann, K.H.; Schubiger, M.; Vogt, K.E.; Rudolph, U.; Mohler, H. GABAA receptors as a substrate for the anxiolytic action of valeric acid, a major constituent of valerian root extracts. Neuropharmacology 2009, 56, 174–181. [CrossRef]

48. Patočka, J.; Jakl, J. Biomedical and chemical constituents of Valeriana officinalis. J. Appl. Biomed. 2010, 8, 11–18. [CrossRef]

49. Yuan, C.-S.; Mehendale, S.; Xiao, Y.; Aung, H.H.; Xie, J.-T.; Ang-Lee, M.K. The Gamma-Aminobutyric Acidergic Effects of Valerian and Valerene Acid on Rat Brainstem Neuronal Activity. Anesth. Analg. 2004, 103, 353–358. [CrossRef] [PubMed]

50. Mineo, L.; Concerto, C.; Patel, D.; Mayorga, T.; Paula, M.; Chusid, E.; Aguglia, E.; Battaglia, F. Valeriana officinalis Root Extract Modulates Cortical Excitatory Circuits in Humans. Neuropharmacology 2017, 115, 46–51. [CrossRef] [PubMed]

51. Khom, S.; Baburin, I.; Timin, E.; Hohaus, A.; Trauner, G.; Kopp, B.; Hering, S. Valerene acid potentiates and inhibits GABA(A) receptors: Molecular mechanism and subunit specificity. Neuropharmacology 2007, 53, 178–187. [CrossRef] [PubMed]

52. Alexeev, M.; Grosenbaugh, D.K.; Mott, D.D.; Fisher, J.L. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors. Neuropharmacology 2012, 62, 2507–2514. [CrossRef] [PubMed]

53. Qu, W.M.; Yue, X.F.; Sun, Y.; Fan, K.; Chen, C.R.; Hou, Y.P.; Urade, Y.; Huang, Z.L. Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice. Br. J. Pharmacol. 2012, 167, 587–598. [CrossRef]

54. Squires, R.F.; Ati, J.; Witt, M.R.; Kahnberg, P.; Saederup, E.; Sterner, O.; Nielsen, M. Honokiol and magnolol increase the number of [3H] muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites. Neurochem. Res. 1999, 24, 1593–1602. [CrossRef]

55. Li, N.; Liu, J.; Wang, M.; Yu, Z.; Zhu, K.; Gao, J.; Wang, C.; Sun, J.; Chen, J.; Li, H. Sedative and hypnotic effects of Schizandrin B through increasing GABA/Glu ratio and upregulating the expression of GABA(A) in mice and rats. Biomed. Pharmacother. 2018, 103, 509–516. [CrossRef]

56. Wang, M.; Li, N.; Jing, S.; Wang, C.; Sun, J.; Li, H.; Liu, J.; Chen, J. Schisandrin B exerts hypnotic effects in PCPA-treated rats by increasing hypothalamic 5-HT and γ-aminobutyric acid levels. Exp. Ther. Med. 2020, 20, 142. [CrossRef] [PubMed]

57. Zhang, C.; Zhao, X.; Mao, X.; Liu, A.; Liu, Z.; Li, X.; Bi, K.; Jia, Y. Pharmacological evaluation of sedative and hypnotic effects of schizandrin through the modification of pentobarbital-induced sleep behaviors in mice. Eur. J. Pharmacol. 2014, 744, 157–163. [CrossRef]

58. Emadi, F.; Yassa, N.; Hadjikouchoudi, A.; Beyer, C.; Sharifzadeh, M. Sedative effects of Iranian Artemisia annua in mice: Possible benzodiazepine receptors involvement. Pharm. Biol. 2011, 49, 784–788. [CrossRef]

59. Kavvadias, D.; Abou-Mandour, A.A.; Czygan, F.C.; Beckmann, H.; Sand, P.; Riederer, P.; Schreier, P. Identification of benzodiazepines in Artemisia dracunculus and Solanum tuberosum rationalizing their endogenous formation in plant tissue. Biochem. Biophys. Res. Commun. 2000, 269, 290–295. [CrossRef]
85. Lozada-Lechuga, J.; Villarreal, M.L.; Fliniaux, M.A.; Bensaddek, L.; Mesnard, F.; Gutierrez Mdel, C.; Cardoso-Taketa, A.T. Isolation of jacaranone, a sedative constituent extracted from the flowers of the Mexican tree Ternstroemia pringlei. J. Ethnopharmacol 2010, 127, 551–554. [CrossRef] [PubMed]

86. Khosravi, M.; Khakpour, S.; Adibi, L.; Jahromy, M.H. A Study of the Effect of Citrus aurantium L. Essential Oil on Anxiety and Its Interaction with GABAergic Pathways in Male Mice. J. Behav. Brain Sci. 2014, 4, 470–476. [CrossRef] [PubMed]

87. Romero, K.; Goparaju, B.; Russo, K.; Westover, M.B.; Bianchi, M.T. Alternative remedies for insomnia: A proposed method for personalized therapeutic trials. Nat. Sci. Sleep 2017, 9, 97–108. [CrossRef] [PubMed]

88. Leach, M.J.; Page, A.T. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med. Rev. 2015, 24, 1–12. [CrossRef] [PubMed]

89. Liu, L.; Liu, C.; Wang, Y.; Wang, P.; Li, Y.; Li, B. Herbal Medicine for Anxiety, Depression and Insomnia. Curr. Neuropharmacol. 2015, 13, 481–493. [CrossRef] [PubMed]

90. Shao, J.; Zheng, X.; Qu, L.; Zhang, H.; Yuan, H.; Hui, J.; Mi, Y.; Ma, P.; Fan, D. Ginsenoside Rg5/Rk1 ameliorated sleep via regulating the GABAergic-serotonergic signaling pathway in a rodent model. Food Funct. 2020, 11, 1245–1257. [CrossRef] [PubMed]

91. Lemaire, P.A.; Adosraku, R.K. An HPLC method for the direct assay of the serotonin precursor, 5-hydroxytryptophan, in seeds of Griffonia simplicifolia. Phytochem. Anal. 2002, 13, 333–337. [CrossRef] [PubMed]

92. Lu, K.; Gray, M.A.; Oliver, C.; Liley, D.T.; Harrison, B.J.; Bartholomewsz, C.F.; Phan, K.L.; Nathan, P.J. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum. Psychopharmacol. 2004, 19, 457–465. [CrossRef] [PubMed]

93. López, V.; Nielsen, B.; Solas, M.; Ramírez, M.J.; Jäger, A.K. Exploring Pharmacological Mechanisms of Lavender (Lavandula angustifolia) Essential Oil on Central Nervous System Targets. Front. Pharmacol. 2017, 8. [CrossRef] [PubMed]

94. Cho, S.M.; Shimizu, M.; Lee, C.J.; Han, D.S.; Jung, C.K.; Jo, J.H.; Kim, Y.M. Hypnotic effects and binding studies for GABA(A) and 5-HT(2C) receptors of traditional medicinal plants used in Asia for insomnia. J. Ethnopharmacol. 2010, 132, 225–232. [CrossRef] [PubMed]